Create Account | Sign In: Author or Forum

 
 
News  |  Journals  |  Conferences  |  Blogs  |  Articles  |  Forums  |  Twitter    
 

 Headlines:

 

Category: Family Medicine | Gynecology | Infections | AIDS | Internal Medicine | Nursing | Pediatrics | Pharmacy | Journal

Back to Journal Articles

Tenofovir Disoproxil Fumarate Doesn’t Impact Fetal Growth

Last Updated: May 08, 2012.

 

Anti-HIV drug doesn't affect newborn size, but may delay growth during first year

Share |

Comments: (0)

Tell-a-Friend

 

  Related
 
Maternal use of the anti-HIV drug tenofovir disoproxil fumarate does not affect fetal growth but may lead to a delayed effect on infant growth in the first year, according to a study published online Feb. 29 in AIDS.

TUESDAY, May 8 (HealthDay News) -- Maternal use of the anti-HIV drug tenofovir disoproxil fumarate (TDF) does not affect fetal growth but may lead to a delayed effect on infant growth in the first year, according to a study published online Feb. 29 in AIDS.

George K. Siberry, M.D., M.P.H., from the National Institutes of Health in Bethesda, Md., and colleagues assessed the effect of TDF on early growth parameters in 2,029 HIV-exposed, uninfected (HEU) infants at birth and at 1 year of age. Growth parameters included small for gestational age (SGA); low birth weight (LBW, <2.5 kg); weight-for-age z-scores (WAZ); length-for-age z-scores (LAZ); and head circumference-for-age z-scores (HCAZ).

The researchers found that TDF usage increased from 14 percent in 2003 to 43 percent in 2010, and was used by 21 percent of the HIV-infected mothers. At birth there was no difference in SGA, LBW, and newborn LAZ and HCAZ for those exposed to combination regimens with or without TDF. At age 1 year, significantly lower adjusted mean LAZ (−0.17 versus −0.03; P = 0.04) and HCAZ (0.17 versus 0.42; P = 0.02) were seen for infants exposed to combination regimens containing TDF than those without TDF.

"The slightly lower mean LAZ and HCAZ observed at age 1 year in TDF-exposed infants are of uncertain significance but underscore the need for additional studies of growth outcomes after TDF use during pregnancy," the authors write.

Abstract
Full Text (subscription or payment may be required)

Copyright © 2012 HealthDay. All rights reserved.


Previous: ACOG: Perinatal Mortality Higher in Out-of-Hospital Births Next: Self-Disclosure Linked to Activation of Reward in Brain

Reader comments on this article are listed below. Review our comments policy.


Submit your opinion:

Name:

Email:

Location:

URL:

Remember my personal information

Notify me of follow-up comments?

advertisement.gif (61x7 -- 0 bytes)
 

Are you a Doctor, Pharmacist, PA or a Nurse?

Join the Doctors Lounge online medical community

  • Editorial activities: Publish, peer review, edit online articles.

  • Ask a Doctor Teams: Respond to patient questions and discuss challenging presentations with other members.

Doctors Lounge Membership Application

 
     

 advertisement.gif (61x7 -- 0 bytes)

 

 

Useful Sites
MediLexicon
  Tools & Services: Follow DoctorsLounge on Twitter Follow us on Twitter | RSS News | Newsletter | Contact us
Copyright © 2001-2014
Doctors Lounge.
All rights reserved.

Medical Reference:
Diseases | Symptoms
Drugs | Labs | Procedures
Software | Tutorials

Advertising
Links | Humor
Forum Archive
CME | Conferences

Privacy Statement
Terms & Conditions
Editorial Board
About us | Email

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.